Oral Scientific Session
The Study of Efficacy and Safety of Robotic Stereotactic Body Radiation Therapy (SBRT) for Locally Hepatocellular Carcinoma (HCC) Patients: Midterm Results of a Multi-institutional, Single-Arm Phase 2 Trial (NCT 02363218)

https://doi.org/10.1016/j.ijrobp.2016.06.345Get rights and content

Section snippets

Purpose/Objective(s)

The primary objective of the phase II trial was to evaluate the efficacy and safety of robotic stereotactic body radiation therapy (SBRT) in treatment of the patients with locally primary hepatocellular carcinoma (HCC).

Materials/Methods

Three hospitals in China participated in this study from February 2013 to December 2015. Inclusion criteria were that Child-Pugh A patients with the maximum diameter of a single lesion was less than 5 cm whereas the maximum diameter of each lesion was not more than 3 cm when the number of lesions was less than 3. All enrolled patients were over 18 with more than 6-month life expectancy, the un-irradiated liver volume should be more than 750 cc, ECOG score was 0, 1, or 2 and the lesion was

Results

Fifty-eight patients were included in this study, median follow-up was 12 months, 47 were male, and 11 were female. The median GTV volume was 7.5 mL. The LC rate was 100% at 1 and 2 years. Among the 58 patients, 10 (17.2%) patients showed a complete response (CR), 28 (48.3%) patients showed a partial response (PR), 20 (34.5%) patients showed a stable disease (SD), and effective rate in the trial group (CR + PR) was 65.5%. The median time to progression was 9 months (7-33 months). The 1 and

Conclusion

Robotic SBRT achieved high local control and with mild adverse effect for locally primary hepatocellular carcinoma (HCC) patients. The results showed SBRT is a safe and effective method in the treatment of HCC in unresectable Child-Pugh A patients.

References (0)

Cited by (0)

Author Disclosure: P. Wang: None. Y. Song: None. H. Zhang: None. P. Liang: None. X. Liu: None. Z. Yuan: None.

View full text